NET SALES

3 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

NET SALES

NOTE 3. NET SALES

The following table presents the disaggregation of net sales by revenue recognition model (in thousands):

	Three months ended September 30,
	2024		2023
Net Sales:
Over-time revenue recognition	$	47	$	190
Point-in-time revenue recognition		14,845		11,748
Total net sales	$	14,892	$	11,938

The timing of revenue recognition, billings, and cash collections results in billed accounts receivables, unbilled receivables (presented as deferred costs on our condensed consolidated balance sheets) and customer advances and deposits (presented as deferred revenue on our condensed consolidated balance sheets), where applicable. Amounts are generally billed as work progresses in accordance with agreed upon milestones. The over-time revenue recognition model consists of non-recurring engineering (“NRE”) and prototype services and typically relates to NRE services related to the evaluation, design or customization of a medical device and is typically recognized over time utilizing an input measure of progress based on costs incurred compared to the estimated total costs upon completion. During the three months ended September 30, 2024 and 2023, we recorded $14,000 and $0, respectively, of revenue that had been included in deferred revenue in the prior year. The revenue recognized from the contract liabilities consisted of satisfying our performance obligations during the normal course of business.

The following tables summarize our contract assets and liability balances (in thousands):

	As of and for the Three Months Ended September 30,
	2024			2023
Contract assets beginning balance	$	262		$	494
Expenses incurred during the year		57			219
Amounts reclassified to cost of sales		(102	)		(105	)
Amounts allocated to discounts for standalone selling price		(6	)		(17	)
Contract assets ending balance	$	211		$	591

	As of and for the Three Months Ended September 30,
	2024			2023
Contract liabilities beginning balance	$	14		$	—
Payments received from customers		—			43
Amounts reclassified to revenue		(14	)		(43	)
Contract liabilities ending balance	$	—		$	—